Protecting Free Vaccines Act

1) What happened: On September 18, 2025, Rep. Pallone (D-NJ) introduced HR5448, the Protecting Free Vaccines Act, in the House. The bill mandates that Medicare, Medicaid, CHIP, and private group/individual health plans cover all ACIP-recommended vaccines as of October 25, 2024, with zero cost-sharing, effective through January 1, 2030. The bill is in early legislative stages, having been referred to the House Committees on Energy and Commerce, Ways and Means, and Education and Workforce. 2) Money trail: This bill does not authorize or appropriate any specific dollar amount. It imposes a coverage MANDATE on existing government and private insurance programs. For insurers, this means absorbing the full acquisition and administration cost of vaccines for members without cost-sharing offsets. For manufacturers, it increases the addressable market by removing patient price sensitivity. The Congressional Budget Office would need to score this as increased federal spending through Medicare and Medicaid cost increases, and as a private-sector mandate on commercial insurers. 3) Winners and losers: Vaccine manufacturers are structural winners. Pfizer ($PFE) has a broad portfolio of ACIP-recommended vaccines (Prevnar, Abrysvo, Comirnaty, TicoVac) that would see increased uptake. Moderna ($MRNA) benefits for Spikevax in seasonal COVID-19 vaccination cycles. Health insurers are structural losers: UnitedHealth ($UNH), with its large Medicare Advantage and commercial membership, faces direct claims cost increases. CVS ($CVS) has offsetting exposure: Aetna (insurance) loses, CVS Pharmacy (vaccine administration) gains from increased foot traffic and administration fees. 4) Real market data analysis (as of April 30, 2026): Pfizer at $26.26 is down 5.44% over 30 days and near the low end of its 52-week range ($21.97-$28.75). Moderna at $45.72 has fallen 13.49% in the last 7 days alone and 5.2% over 30 days, amid a steep 7-day decline from $54.68. Conversely, UnitedHealth at $370.74 is up 41.62% over 30 days and 4.56% in the last 7 days, suggesting market optimism on other business lines or sector rotation. CVS at $83.90 has gained 19.62% over 30 days and 6.39% in 7 days, trading near its 52-week high ($85.15). The current price action shows insurers outperforming manufacturers in the near term, which may reflect broader market dynamics rather than this early-stage bill. 5) Legislative timeline: HR5448 is in the earliest stage — referred to three committees with no hearings, markups, or votes yet. It has 72 cosponsors, a sign of moderate Democratic support, but faces an uncertain path in a divided 119th Congress. A Senate companion bill (S2857) was also introduced and referred to HELP, increasing the probability of coordinated legislative effort, but both bills are likely a year or more from any floor vote.